Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$228.41
+1.0%		$247.96
$186.05
▼
$282.15
$14.25B0.38703,162 shs820,537 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.50
-0.7%		$75.41
$52.75
▼
$93.42
$13.00B0.972.91 million shs2.06 million shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$19.12
+2.1%		$19.82
$16.24
▼
$37.50
$3.70B0.572.43 million shs1.57 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.95
+3.7%		$15.28
$12.07
▼
$29.23
$14.32B-1.514.60 million shs8.17 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.87%-0.89%-16.45%-18.45%+7.22%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+1.24%+1.50%-10.53%-14.52%+22.61%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-0.27%-0.53%-13.01%-32.83%-40.46%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.23%+5.61%-1.65%+10.33%-21.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$228.41
+1.0%		$247.96
$186.05
▼
$282.15
$14.25B0.38703,162 shs820,537 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.50
-0.7%		$75.41
$52.75
▼
$93.42
$13.00B0.972.91 million shs2.06 million shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$19.12
+2.1%		$19.82
$16.24
▼
$37.50
$3.70B0.572.43 million shs1.57 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.95
+3.7%		$15.28
$12.07
▼
$29.23
$14.32B-1.514.60 million shs8.17 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.87%-0.89%-16.45%-18.45%+7.22%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+1.24%+1.50%-10.53%-14.52%+22.61%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-0.27%-0.53%-13.01%-32.83%-40.46%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.23%+5.61%-1.65%+10.33%-21.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7536.05% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$105.4258.53% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.53
Moderate Buy$55.79191.77% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.53
Moderate Buy$28.6159.37% Upside

Current Analyst Ratings Breakdown

Latest LEGN, ASND, SMMT, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$157.00 ➝ $156.00
10/6/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
10/2/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/30/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$41.00
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform
(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.49N/AN/A($2.97) per share-76.91
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M25.89N/AN/A($10.77) per share-6.17
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$1.03B3.60N/AN/A$5.43 per share3.52
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.7225.58N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$296.80M-$0.25N/A16.34N/A-7.21%-8.71%-5.40%11/11/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest LEGN, ASND, SMMT, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.6133N/AN/AN/A$269.01 millionN/A
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/11/2026Q2 2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$0.07$0.09+$0.02$0.18$355.96 million$387.50 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/A
3.04
2.94
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,965193.77 million193.73 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?
October 7 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-jumps-36-whats-next-2026-10-07/
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
October 5 at 11:40 AM  |  zacks.comhttps://www.zacks.com/stock/news/3000206/smmt-inks-deal-with-azn-daiichi-to-study-ivonescimab-datroway-combos?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3000206
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-7-3-230615020.html
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696045/daiichi-sankyo-astrazenca-summit-partner-to-evaluate-datroway-plus-ivonescimab.aspx
Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What Happened
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078640
Summit agrees to $2 billion AstraZeneca equity investment
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078180
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001197318/en/summit-therapeutics-announces-clinical-trial-collaboration-with-astrazeneca-and-daiichi-sankyo-to-evaluate-ivonescimab-in-combination-with-trop2-directed-adc-datroway/
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001131464/en/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-summit-therapeutics-to-evaluate-datroway%c2%ae-in-combination-with-ivonescimab-across-multiple-tumor-types/
What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-summit-therapeutics-smmt-gain-220553806.html
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-2-billion-vote-confidence-151701810.html
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4883679/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-argenx-se-argx-and-obsidian-therapeutics-obx/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-up-71-whats-next-2026-09-30/
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/astrazenecas-2-billion-vote-of-confidence-leaves-summit-therapeutics-trading-well-below-street-targets/?utm_source=snapi
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-apos-2-billion-investment-190315458.html
Summit Therapeutics PLC ADR (SMMT)
September 30, 2026  |  ca.investing.comhttps://ca.investing.com/equities/summit-therapeutics-plc-news
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
September 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997738/summit-shares-jump-on-2b-strategic-investment-from-astrazeneca?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2997738
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-still-a-buy-2026-09-29/
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
September 29, 2026  |  invezz.comI
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
September 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099267?snapi
AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694521/astrazeneca-invests-2-billion-in-summit-expands-cancer-drug-collaboration-stock-up.aspx
Summit Therapeutics rises after AstraZeneca commits $2B investment
September 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-therapeutics-rises-after-astrazeneca-commits-2b-investment/ar-AA2d9pUc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$228.41 +2.36 (+1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$224.26 -4.15 (-1.82%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$66.50 -0.46 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$67.22 +0.72 (+1.08%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$19.12 +0.40 (+2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$19.11 -0.01 (-0.03%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.95 +0.64 (+3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$17.93 -0.02 (-0.08%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas